Gonal-f
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | FOLLISTIM AQ | — | 2010-06-28 – 2011-08-22 | fda.gov ↗ |
| Label expansion | US (FDA) | GONAL-F | — | 2000-05-24 | fda.gov ↗ |
| Approved | US (FDA) | FOLLISTIM | — | 1997-09-29 | fda.gov ↗ |
| Approved | EU (EMA) | GONAL-f | — | 1995-10-20 | europa.eu ↗ |
Trials 50 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03356964 | Nov 2017 → Feb 2020 | progesterone resistance | ART Fertility Clinics LLC | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT07269327 | Nov 2025 → Mar 2026 | infertility disorder | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT06864793 | Apr 2025 → Feb 2026 overdue | female infertility | Qilu Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06414096 | Oct 2024 → Nov 2025 overdue | female infertility, obesity disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT03535103 | Jun 2018 → Dec 2019 | female infertility | Alphamab Jilin Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03857230 | Oct 2015 → May 2016 | — | IVFarma LLC | Completed | No outcome recorded |
| Phase 1 | NCT02459418 | May 2015 → May 2016 | — | Fertility Biotech AG | Completed | No outcome recorded |
| Phase 1 | NCT02592031 | Feb → May 2009 | — | Merckle GmbH | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00553514 | Dec 2007 → Mar 2009 | female infertility | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 2 | NCT00505752 | Jan 2007 → Sep 2008 | infertility disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00064987 | Apr 2001 → Oct 2012 | Kallmann syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02349945 | Jan 2011 → Dec 2014 | male infertility | Azienda USL Modena | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT07340827 | Feb 2026 → Jul 2028 expected | infertility disorder | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Recruiting | No outcome recorded |
| Phase 3 | NCT05266924 | Jul 2022 → Aug 2023 | female infertility | Bharat Serums and Vaccines Limited | Unknown | No outcome recorded |
| Phase 3 | NCT05263388 | Jul 2022 → Apr 2024 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04773353 | Dec 2021 → Dec 2023 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00749853 | May 2015 | infertility disorder | Medical University of Vienna | Suspended | No outcome recorded |
| Phase 3 | NCT02454556 | Apr 2015 → Dec 2016 | infertility disorder | Gema Biotech S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01121666 | Jun 2010 → Dec 2011 | infertility disorder | Finox AG | Completed | No outcome recorded |
| Phase 3 | NCT02335879 | May 2008 → Aug 2009 | anovulation | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01185782 | Feb → Dec 2007 | female infertility | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT01071200 | Mar 2005 → Apr 2009 | — | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 3 | NCT00378001 | Mar 2005 → May 2006 | female infertility | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 3 | NCT01183143 | May 2004 → Mar 2006 | infertility disorder, ovarian disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT01081639 | Nov 2003 → Sep 2004 | infertility disorder, ovarian disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 416 trials | ||||||
| Phase 4 | NCT06571214 | Sep 2024 → Dec 2026 expected | infertility disorder | Nanjing University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04983173 | Nov 2021 → Mar 2026 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| Phase 4 | NCT04430621 | Jul → Aug 2020 | — | Federico II University | Unknown | No outcome recorded |
| Phase 4 | NCT03846544 | Oct 2019 → Sep 2021 | infertility disorder | CRG UZ Brussel | Completed | No outcome recorded |
| Phase 4 | NCT03057574 | Feb → Dec 2017 | female infertility | MinaPharm Pharmaceuticals | Unknown | No outcome recorded |
| Phase 4 | NCT02719093 | Jul 2016 → Jul 2017 | male infertility, varicocele | U.O. Chirurgia Andrologica | Unknown | No outcome recorded |
| Phase 4 | NCT02625519 | Dec 2015 → Jan 2019 | — | Instituto Bernabeu | Unknown | No outcome recorded |
| Phase 4 | NCT02834117 | May 2015 → Feb 2018 | infertility disorder | Dr Massin Nathalie | Completed | No outcome recorded |
| Phase 4 | NCT01948804 | Jan → Mar 2014 | — | Pınar Özcan Cenksoy | Unknown | No outcome recorded |
| Phase 4 | NCT01871532 | Jul 2013 → Mar 2014 | infertility disorder | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 4 | NCT01081626 | Mar 2009 → Mar 2011 | female infertility | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01210144 | Aug 2008 → Aug 2010 | — | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 4 | NCT00575302 | Dec 2007 → Dec 2009 | infertility disorder | Centre Hospitalier Chretien | Withdrawn | No outcome recorded |
| Phase 4 | NCT00439829 | Feb 2007 → May 2010 | female infertility | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT00334425 | Apr 2006 → ? | infertility disorder | Central Jutland Regional Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00249834 | Sep 2004 → Jan 2006 | infertility disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07409493 | Jan 2026 → Jun 2028 expected | infertility disorder | Hanoi Medical University | Recruiting | No outcome recorded |
| — | NCT05103228 | Dec 2021 → Jul 2023 | infertility disorder, ovarian dysfunction | Peter Kovacs MD | Completed | No outcome recorded |
| — | NCT04134130 | Sep → Dec 2019 | prostate cancer | Lund University | Completed | No outcome recorded |
| — | NCT03098199 | Oct 2015 → Dec 2017 | infertility disorder | Reproductive Specialists of New York | Completed | No outcome recorded |
| — | NCT02478775 | Jul 2015 → Jun 2021 | infertility disorder, obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT02418533 | Mar 2015 → Apr 2017 | infertility disorder | Main Line Fertility Center | Completed | No outcome recorded |
| — | NCT01421095 | Jan 2011 → Dec 2026 expected | cancer, infertility disorder | University of California, San Diego | Active not recruiting | No outcome recorded |
| — | NCT00989781 | Sep 2009 → Sep 2013 | polycystic ovary syndrome | University of California, San Diego | Completed | No outcome recorded |
| — | NCT01223079 | Dec 2005 → Dec 2007 | — | Reproductive Medicine Associates of New Jersey | Completed | No outcome recorded |
Also used as a comparator or background therapy in 83 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01604044 Comparator | May 2012 → Sep 2013 | female infertility | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 1 | NCT01477073 Comparator | Oct 2011 → Apr 2012 | female infertility | Glycotope GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01354886 Comparator | Apr → Oct 2011 | female infertility | Glycotope GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01141270 Comparator | Jan → Aug 2009 | — | Polymun Scientific GmbH | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02179255 Background | Aug 2014 → Jun 2021 | female infertility | Center for Human Reproduction | Unknown | No outcome recorded |
| Phase 1/2 | NCT00823121 Comparator | Aug 2008 → Feb 2009 | — | Yazd Research & Clinical Center for Infertility | Unknown | No outcome recorded |
| Phase 1/2 | NCT00823004 Comparator | Jun 2008 → Feb 2009 | ovarian hyperstimulation syndrome | Yazd Research & Clinical Center for Infertility | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT01794208 Comparator | Jan → Jul 2013 | infertility disorder | Glycotope GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01426386 Comparator | Sep 2011 → Apr 2012 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01337531 Comparator | May → Nov 2011 | polycystic ovary syndrome | Genesis Center for Fertility & Human Pre-Implantation Genetics | Unknown | No outcome recorded |
| Phase 2 | NCT01204840 Comparator | Sep 2010 → May 2015 | infertility disorder, ovarian dysfunction | Ottawa Fertility Centre | Completed | No outcome recorded |
| Phase 2 | NCT01075815 Background | Nov 2008 → Oct 2010 | infertility disorder, ovarian disorder | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 2 | NCT01079949 Comparator | Nov 2007 → Oct 2010 | female infertility | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 2 | NCT01110707 Background | Jan 2005 → Nov 2006 | infertility disorder, ovarian disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT01735422 Background | Dec 1999 → Jul 2001 | female infertility | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01590173 Comparator | Jan 2012 → Jul 2016 | infertility disorder | National and Kapodistrian University of Athens | Completed | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT07346235 Comparator | Mar 2026 → Jan 2028 expected | female infertility | American Hospital 2 Kosovo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06173869 Comparator | Mar 2024 → May 2025 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT06091436 Comparator | Mar → Dec 2023 | infertility disorder | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04935073 Background | Jun 2021 → Dec 2022 | female infertility | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04842825 Comparator | Apr 2021 → Dec 2022 | female infertility | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04537078 Comparator | Sep 2020 → Mar 2021 | female infertility | El Shatby University Hospital for Obstetrics and Gynecology | Completed | No outcome recorded |
| Phase 3 | NCT05149924 Comparator | Oct 2018 → Oct 2019 | female infertility | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03296527 Comparator | Dec 2017 → Jan 2020 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03088137 Comparator | Feb 2017 → Aug 2018 | female infertility | IVFarma LLC | Completed | No outcome recorded |
| Phase 3 | NCT03506243 Comparator | Apr 2015 → Sep 2016 | female infertility | Hangzhou YuYuan Bioscience Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01956123 Comparator | Mar 2014 → May 2015 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02047227 Comparator | Jan 2014 → Aug 2015 | infertility disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT01687712 Comparator | Nov 2013 → Sep 2015 | infertility disorder | Fertility Biotech AG | Completed | No outcome recorded |
| Phase 3 | NCT01923194 Comparator | Oct 2013 → Jul 2015 | anovulation | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01922193 Comparator | Oct 2013 → Feb 2015 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01956110 Comparator | Oct 2013 → May 2015 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01816321 Comparator | Mar 2013 → May 2016 | infertility disorder, ovarian dysfunction | University Hospital Brussels | Completed | No outcome recorded |
| Phase 3 | NCT01653743 Background | Sep 2012 → Nov 2014 | anovulation, hypothalamic dysfunction, polycystic ovary syndrome | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT01497197 Background | May 2012 → Jan 2014 | infertility disorder, pituitary deficiency | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 3 | NCT01297465 Comparator | May 2011 → Oct 2012 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT01044862 Comparator | Jun 2010 → Oct 2013 | infertility disorder, pregnancy disorder | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT00884221 Comparator | Jul 2009 → Jul 2010 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01820728 Comparator | Jan 2007 → Oct 2012 | anovulation, infertility disorder | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01084265 Background | Feb 2004 → Dec 2005 | hypogonadism | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00335725 Comparator | Mar 2003 → Dec 2005 | infertility disorder | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 3 | NCT00669786 Comparator | — | — | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 431 trials | ||||||
| Phase 4 | NCT07121751 Comparator | Sep 2025 → Aug 2026 overdue | infertility disorder | Dunamenti REK Istenhegyi IVF Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05405686 Background | May → Aug 2023 | female infertility due to oocyte meiotic arrest | CRG UZ Brussel | Withdrawn | No outcome recorded |
| Phase 4 | NCT05815719 Comparator | Nov 2022 → Apr 2023 | infertility disorder | Instituto Bernabeu | Completed | No outcome recorded |
| Phase 4 | NCT04992468 Background | Oct 2021 → Apr 2023 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| Phase 4 | NCT04997525 Comparator | Apr 2021 → May 2024 | infertility disorder | Copenhagen University Hospital at Herlev | Completed | No outcome recorded |
| Phase 4 | NCT04719000 Background | Feb 2021 → Aug 2027 expected | infertility disorder | Fundacion Dexeus | Recruiting | No outcome recorded |
| Phase 4 | NCT04724486 Background | Aug 2020 → Mar 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04727684 Background | Aug 2020 → Feb 2022 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04724343 Background | Dec 2019 → Jan 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04727671 Background | Dec 2019 → Aug 2021 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT03252223 Comparator | Oct 2017 → Jun 2021 | anovulation, polycystic ovary syndrome | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT03177538 Comparator | Sep 2017 → Nov 2018 | female infertility | D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology | Completed | No outcome recorded |
| Phase 4 | NCT03118830 Comparator | Apr → Nov 2017 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02892942 Background | Jan 2017 → Feb 2019 | infertility disorder | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT03181685 Comparator | Dec 2016 → Dec 2019 | infertility disorder | Andros Day Surgery Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT02554279 Comparator | Aug 2015 → Jan 2017 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01969201 Comparator | Jan 2014 → Jun 2016 | infertility disorder | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 4 | NCT01760278 Background | Dec 2012 → Mar 2013 | aneuploidy, low implantation of placenta, pregnancy disorder with abortive outcome | Bloom IVF and Fertility Centre | Unknown | No outcome recorded |
| Phase 4 | NCT02140515 Comparator | Nov 2012 → Dec 2015 | infertility disorder | Royan Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01345812 Comparator | Apr 2011 → Jul 2012 | — | University of Aarhus | Terminated | No outcome recorded |
| Phase 4 | NCT01267604 Comparator | Dec 2010 → Dec 2013 | infertility disorder | AGUNCO Obstetrics and Gynecology Centre | Withdrawn | No outcome recorded |
| Phase 4 | NCT01225835 Comparator | Oct 2010 → Jan 2013 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01403532 Comparator | Sep 2009 → Dec 2012 | Kallmann syndrome | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02437032 Comparator | Apr 2009 → Sep 2012 | infertility disorder | IVI Madrid | Completed | No outcome recorded |
| Phase 4 | NCT02108223 Comparator | Jan 2009 → Apr 2011 | infertility disorder | Sisli Hamidiye Etfal Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00829244 Comparator | Aug 2008 → Jan 2010 | infertility disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01365936 Comparator | Jan → Jun 2008 | polycystic ovary syndrome | Zekai Tahir Burak Women's Health Research and Education Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00830492 Comparator | Jan → Dec 2008 | ovarian hyperstimulation syndrome | Yazd Research & Clinical Center for Infertility | Completed | No outcome recorded |
| Phase 4 | NCT00328926 Comparator | Mar 2006 → May 2012 | hypogonadotropic hypogonadism | EMD Serono | Terminated | No outcome recorded |
| Phase 4 | NCT00257556 Comparator | Oct 2005 → Jul 2008 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00553293 Comparator | Aug 2003 → Nov 2004 | infertility disorder | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT06481696 Comparator | Jun 2024 → Dec 2025 | infertility disorder | Andros Day Surgery Clinic | Unknown | No outcome recorded |
| — | NCT07128394 Background | Feb 2024 → Sep 2026 expected | female infertility | Nanjing University | Recruiting | No outcome recorded |
| — | NCT05670795 Background | Jan 2023 → May 2024 | infertility disorder | Bezmialem Vakif University | Unknown | No outcome recorded |
| — | NCT05567731 Background | Oct 2022 → Dec 2023 | infertility disorder | Tanta University | Completed | No outcome recorded |
| — | NCT05089344 Background | Oct 2021 → Oct 2022 | female infertility | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| — | NCT04325295 Comparator | Dec 2020 → Jun 2022 | anovulation, polycystic ovary syndrome | Assiut University | Unknown | No outcome recorded |
| — | NCT03914651 Comparator | Apr 2019 → Dec 2022 | infertility disorder | Reproductive & Genetic Hospital of CITIC-Xiangya | Unknown | No outcome recorded |
| — | NCT03737253 Comparator | Sep 2016 → Dec 2021 | female infertility | Lund University | Completed | No outcome recorded |
| — | NCT02244866 Comparator | Oct 2012 → Apr 2014 | infertility disorder | Vietnam National University | Completed | No outcome recorded |
| — | NCT01634724 Background | Jul 2012 | — | Nanjing University | Unknown | No outcome recorded |
Evidence & citations 33 cited values
Every value below carries the sentence it was read from. 140 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gonal-F | “Two weeks later, if E2 in serum was ≤40 pg/ml and absence of follicular activity was detected, the stimulation of ovaries was started by recombinant follicle-stimulating...” NCT01634724 ↗51“Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter...” NCT00749853 ↗ “This is an open-label, Phase 3, randomized, two arms, multicenter, prospective, experimental study of Folitime® (a new biosimilar formulation of r-hFSH, follitropin alfa)...” NCT02454556 ↗ “for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin” NCT01590173 ↗ “Women randomized to the day 1 treatment group will be instructed to begin ovarian stimulation therapy (Gonal-f, Serono Canada) on day 1” NCT00439829 ↗ “On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger.” NCT03914651 ↗ “stimulation with hMG (Menogon; Ferring Pharmaceuticals. Istanbul) or rFSH (Gonal-F; Serono Istanbul).” NCT01365936 ↗ “recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®)” NCT04992468 ↗ “recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU” NCT05089344 ↗ “gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F)” NCT01204840 ↗ “with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany)” NCT05567731 ↗ “150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.” NCT00830492 ↗ “Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6” NCT01497197 ↗ “Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.” NCT04134130 ↗ “recombinant FSH (Gonal-F, Serono, Aubonne, Switzerland)” NCT00823004 ↗ “Gonal-f®: follitropin alpha, administration of 300 U” NCT00575302 ↗ “Gonal-F is a recombinant FSH preparation.” NCT00335725 ↗ “300 IU rhFSH (Gonal-F®- Merck)” NCT04719000 ↗ “Follitropin Alfa (GONAL-F)” NCT01956123 ↗ “Follitropin alfa (Gonal-F)” NCT03857230 ↗ “Follitropin alfa (Gonal-f)” NCT03088137 ↗ “Follitropin Alfa (GONAL-F)” NCT01956110 ↗ “GONAL-F (Follitropin Alfa)” NCT05263388 ↗ “fix dose r-FSH (Gonal-f)” NCT02108223 ↗ “Gonal-f 150 IU QD” NCT01477073 ↗ “r-hFSH (Gonal F)” NCT01223079 ↗ “Gonal-f” NCT03181685 ↗ |
| Known as | Afolia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02459418 ↗ |
| Known as | AFOLIA-150 | “AFOLIA-150 (Follitropin alfa)” NCT01121666 ↗ |
| Known as | Domestic Recombinant Human Follitropin | “Domestic Recombinant Human Follitropin (Gonal-F) for Injection” NCT02335879 ↗ |
| Known as | FOLITIME | “This is an open-label, Phase 3, randomized, two arms, multicenter, prospective, experimental study of Folitime® (a new biosimilar formulation of r-hFSH, follitropin alfa)...” NCT02454556 ↗ |
| Known as | follicle stimulating hormone | “Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;” NCT01403532 ↗8“follicle stimulating hormone (FSH) administered subcutaneously” NCT03252223 ↗ |
| Known as | Follitrophin alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01225835 ↗ |
| Known as | Follitropin Alfa | “One-hundred patients with a morphologic aspect of hypospermatogenesis at testicular cytology will take recombinant follitropin alfa 150UI i.m. 3 times/week for at least three month.” NCT02719093 ↗33“Significantly lower mean daily (121.5 versus 167.4 IU; P < 0.001) and total (1288.5 versus 1810.0 IU; P < 0.001) doses of follitropin alfa were administered in the CONSORT group.” PMID 25596910 ↗ Dec 2014 “Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days.” NCT00328926 ↗ “Follitropin alfa is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin” NCT02454556 ↗ “starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day” NCT01653743 ↗ “GONAL-F (Follitropin Alfa)” NCT05263388 ↗ “Follitropin alfa” NCT06864793 ↗ “Follitropin alfa” NCT06864793 ↗ “follitropin alfa” NCT07128394 ↗ |
| Known as | Follitropin alfa (r-hFSH) | “Follitropin alfa (r-hFSH)” NCT02454556 ↗ |
| Known as | Follitropin alpha | “Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin” NCT02834117 ↗ |
| Known as | FSH | “Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;” NCT01403532 ↗3“follicle stimulating hormone (FSH)” NCT00064987 ↗ “Follicle Stimulating Hormone (FSH)” NCT01044862 ↗ “Follicle-stimulating hormone (FSH)” NCT07346235 ↗ |
| Known as | Gonal-F (r-hFSH) | “Gonal-F (r-hFSH)” NCT01084265 ↗ |
| Known as | Gonal-f RFF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01687712 ↗ |
| Known as | Gonapure | “Gonapure” NCT04537078 ↗ |
| Known as | Ovaleap | “recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®)” NCT04992468 ↗1“CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®)” NCT04983173 ↗ |
| Known as | Primapur | “Follitropin alfa (Primapur)” NCT03088137 ↗1“Follitropin alfa (Primapur)” NCT03857230 ↗ |
| Known as | Puregon | “recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®)” NCT04992468 ↗ |
| Known as | QL1012D | “Recombinant Human Follicle Stimulating Hormone Injection (QL1012D) and Gonal-F® in Healthy Female Volunteers” NCT06864793 ↗ |
| Known as | r-hFSH | “The purpose of this study is to assess the Pharmacokinetic (PK) of Recombinant human follicle-stimulating hormone (follitropin alfa) (r-hFSH) and Recombinant human luteinizing...” NCT07269327 ↗8“Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter...” NCT00749853 ↗ “recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU)” NCT01110707 ↗ “The participant will receive r-hFSH, fixed-dose for 5 days” NCT05266924 ↗ “Recombinant human follicle-stimulating hormone (r-hFSH)” NCT01084265 ↗ |
| Known as | recFSH | “Two weeks later, if E2 in serum was ≤40 pg/ml and absence of follicular activity was detected, the stimulation of ovaries was started by recombinant follicle-stimulating...” NCT01634724 ↗ |
| Known as | rechFSH | “Participants will receive fixed combination product of recombinant Follitropin alfa (rechFSH)/lutropin alfa (rechLH) in a 2:1 ratio.” NCT07340827 ↗ |
| Known as | recombinant Follicle Stimulating Hormone (rFSH) | “Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)” NCT02140515 ↗ |
| Known as | recombinant Follicle-Stimulating Hormone | “The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of...” NCT04727684 ↗14“Two weeks later, if E2 in serum was ≤40 pg/ml and absence of follicular activity was detected, the stimulation of ovaries was started by recombinant follicle-stimulating...” NCT01634724 ↗ “Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm...” PMID 32416978 ↗ May 2020 “recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®)” NCT04992468 ↗ “recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG)” NCT04724486 ↗ “recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH)” NCT05567731 ↗ “recombinant Follicle-Stimulating Hormone (r-FSH)” NCT04727671 ↗ “recombinant follicle-stimulating hormone (r FSH)” PMID 24520446 ↗ Mar 2013 |
| Known as | recombinant FSH | “Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization.” PMID 24520446 ↗ Mar 201322“150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection” NCT02244866 ↗ “225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR).” NCT03846544 ↗ “receiving recombinant FSH (rhFSH) versus rhFSH and rhLH for ovarian stimulation.” NCT04719000 ↗ “150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.” NCT00830492 ↗ “Patients receive recombinant FSH starting from day 2-3 of menstrual cycle” NCT07409493 ↗ “using recombinant FSH (r-FSH), injected sc for 3 days at any one dose” NCT03252223 ↗ “same recombinant FSH dose as in her prevoius cycle” NCT07121751 ↗ |
| Known as | Recombinant human Follicle Stimulating Hormone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01071200 ↗ |
| Known as | Recombinant Human Follitropin Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01923194 ↗ |
| Known as | Recominant Follicle Stimulating Hormone (rFSH) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02418533 ↗ |
| Known as | Rekovelle | “recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®)” NCT04992468 ↗ |
| Known as | rFSH | “The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of...” NCT04727684 ↗18“test the hypothesis that intravenous (IV) administration of pulsatile recombinant follicle-stimulating hormone (rFSH) can overcome the clinically evident dysfunctional...” PMID 37276947 ↗ Jun 2023 “Highly purified hMG (hp-hMG) has recently shown better cycle outcome than the recombinant FSH (rFSH)” PMID 18583332 ↗ Jun 2008 “recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®)” NCT04992468 ↗ “recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG)” NCT04724343 ↗ “recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG)” NCT04724486 ↗ “Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)” NCT00669786 ↗ “with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany)” NCT05567731 ↗ “225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR).” NCT03846544 ↗ “using recombinant FSH (r-FSH), injected sc for 3 days at any one dose” NCT03252223 ↗ “compared with daily recombinant FSH (rFSH) in young poor responders?” PMID 29040589 ↗ Nov 2017 “highly purified menotropin (hphMG) and recombinant FSH (rFSH)” PMID 22244781 ↗ Jan 2012 “recombinant Follicle-Stimulating Hormone (r-FSH)” NCT04727671 ↗ “recombinant Follicle Stimulating Hormone (rFSH)” NCT01760278 ↗ “Recombinant FSH (rFSH)” NCT01267604 ↗ |
| Known as | US Gonal-f | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02459418 ↗ |
| Action | Restore | “Pulsatile FSH can partially correct the relative hypogonadotropic hypogonadism of obesity” PMID 37276947 ↗ Jun 2023 |
| Modality | Protein / enzyme biologic | “recombinant follicle-stimulating hormone pretreatment” PMID 24037890 ↗ Sep 2013 |
| Route | Subcutaneous | “75 IU subcutaneous injection daily for four months.” NCT00064987 ↗ |